
DERM
Journey Medical Corp
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.650
Open
7.650
VWAP
7.54
Vol
89.00K
Mkt Cap
131.27M
Low
7.375
Amount
671.15K
EV/EBITDA(TTM)
--
Total Shares
20.01M
EV
136.47M
EV/OCF(TTM)
--
P/S(TTM)
2.85
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
14.93M
+0.53%
--
--
19.52M
+33.46%
--
--
23.40M
+71.8%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Journey Medical Corporation (DERM) for FY2025, with the revenue forecasts being adjusted by -1.6% over the past three months. During the same period, the stock price has changed by 0.13%.
Revenue Estimates for FY2025
Revise Downward

-1.6%
In Past 3 Month
Stock Price
Go Up

+0.13%
In Past 3 Month
2 Analyst Rating

25.16% Upside
Wall Street analysts forecast DERM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DERM is 9.50 USD with a low forecast of 9.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy

25.16% Upside
Current: 7.590

Low
9.00
Averages
9.50
High
10.00

25.16% Upside
Current: 7.590

Low
9.00
Averages
9.50
High
10.00
Alliance Global Partners
Buy
downgrade
$10
2025-05-15
Reason
Alliance Global Partners
Price Target
$10
2025-05-15
downgrade
Buy
Reason
Alliance Global Partners lowered the firm's price target on Journey Medical to $10 from $10.50 and keeps a Buy rating on the shares following the Q1 report. The firm adjusted its model lower due to Journey's legacy business trends.
Lake Street
Thomas Flaten
Strong Buy
Initiates
$9
2024-09-06
Reason
Lake Street
Thomas Flaten
Price Target
$9
2024-09-06
Initiates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Journey Medical Corp (DERM.O) is 97.18, compared to its 5-year average forward P/E of -1.45. For a more detailed relative valuation and DCF analysis to assess Journey Medical Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.45
Current PE
97.18
Overvalued PE
23.49
Undervalued PE
-26.38
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
12.85
Current EV/EBITDA
11.63
Overvalued EV/EBITDA
41.80
Undervalued EV/EBITDA
-16.11
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued
5Y Average PS
1.15
Current PS
2.22
Overvalued PS
1.71
Undervalued PS
0.59
Financials
Annual
Quarterly
FY2025Q1
YoY :
+0.84%
13.14M
Total Revenue
FY2025Q1
YoY :
-67.06%
-3.32M
Operating Profit
FY2025Q1
YoY :
-60.99%
-4.07M
Net Income after Tax
FY2025Q1
YoY :
-66.04%
-0.18
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q1
YoY :
+16.25%
55.44
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
YoY :
-61.32%
-31.00
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
69.1K
USD
3
3-6
Months
818.1K
USD
7
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
27.3K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
69.1K
USD
3
3-6
Months
818.1K
USD
7
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DERM News & Events
Events Timeline
2025-07-14 (ET)
2025-07-14
08:35:18
Journey Medical announces expanded payer coverage for Emrosi

2025-06-24 (ET)
2025-06-24
08:43:20
Journey Medical to join Russell 2000, Russell 3000 Indexes

2025-06-20 (ET)
2025-06-20
08:32:39
Journey Medical announces data analysis from Phase 3 trials of Emrosi

Sign Up For More Events
Sign Up For More Events
News
9.0
07-14NewsfilterJourney Medical Corporation Announces Expanded Payer Coverage for Emrosi™
1.0
06-24NewsfilterJourney Medical to Join Russell 2000® and Russell 3000® Indexes
4.5
06-24SeekingAlphaJourney Medical to join Russell 2000 and 3000 Indexes
Sign Up For More News
People Also Watch

RPTX
Repare Therapeutics Inc
1.560
USD
+0.65%

SWVL
Swvl Holdings Corp
4.180
USD
+2.45%

PDSB
PDS Biotechnology Corp
1.180
USD
-2.48%

INLX
Intellinetics Inc
13.580
USD
0.00%

GEG
Great Elm Group Inc
2.170
USD
+1.40%

RFAC
RF Acquisition Corp
0
USD
-218.52%

TOP
TOP Financial Group Ltd
1.225
USD
-0.41%

HYMC
Hycroft Mining Holding Corporation
3.580
USD
-2.98%

CLRC
ClimateRock
0
USD
-1.42%

NTZ
Natuzzi SpA
2.850
USD
0.00%
FAQ

What is Journey Medical Corp (DERM) stock price today?
The current price of DERM is 7.59 USD — it has decreased -1.04 % in the last trading day.

What is Journey Medical Corp (DERM)'s business?

What is the price predicton of DERM Stock?

What is Journey Medical Corp (DERM)'s revenue for the last quarter?

What is Journey Medical Corp (DERM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Journey Medical Corp (DERM)'s fundamentals?

How many employees does Journey Medical Corp (DERM). have?
